Meros Investment Management LP Raises Stock Position in InMode Ltd. $INMD

Meros Investment Management LP grew its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 404,453 shares of the healthcare company’s stock after purchasing an additional 36,866 shares during the period. InMode comprises about 2.4% of Meros Investment Management LP’s portfolio, making the stock its 20th biggest position. Meros Investment Management LP owned about 0.64% of InMode worth $5,941,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Deutsche Bank AG increased its stake in InMode by 35.9% during the fourth quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company’s stock worth $58,000 after purchasing an additional 1,037 shares during the period. Quadrant Capital Group LLC grew its position in shares of InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after buying an additional 1,091 shares in the last quarter. Leonteq Securities AG acquired a new position in shares of InMode during the fourth quarter worth about $26,000. Plan A Wealth LLC grew its position in shares of InMode by 16.2% during the fourth quarter. Plan A Wealth LLC now owns 12,878 shares of the healthcare company’s stock worth $189,000 after buying an additional 1,793 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in shares of InMode by 9.5% during the fourth quarter. Van ECK Associates Corp now owns 22,693 shares of the healthcare company’s stock worth $333,000 after buying an additional 1,976 shares in the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Stock Performance

Shares of InMode stock opened at $13.57 on Tuesday. InMode Ltd. has a one year low of $12.72 and a one year high of $16.74. The company has a market cap of $859.80 million, a PE ratio of 9.98 and a beta of 1.94. The business has a 50-day simple moving average of $13.92 and a 200-day simple moving average of $14.16.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Wednesday, May 6th. The healthcare company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). The company had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 earnings per share.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on INMD. Barclays set a $19.00 price objective on InMode and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Robert W. Baird lowered their price objective on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, InMode presently has a consensus rating of “Hold” and a consensus target price of $16.00.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.